Work

Pacritinib, a Dual JAK2/FLT3 Inhibitor: An Integrated Efficacy and Safety Analysis Of Phase II Trial Data In Patients With Primary and Secondary Myelofibrosis (MF) and Platelet Counts ≤100,000/µl

Year: 2013

Type: article

Source: Blood

DOI: 10.1182/blood.v122.21.395.395

Authors: Srdan Verstovsek, James P. Dean, Paul Cernohous, Rami S Komrokji, John F. Seymour, Ruben A. Mesa, Mary S Campbell, Susan E. Caldwell, Lixia Wang, Han Myint

Institutions: The University of Texas MD Anderson Cancer Center, Moffitt Cancer Center, Peter MacCallum Cancer Centre, Mayo Clinic, Mayo Clinic in Arizona

Language: English

Topic: Myeloproliferative Neoplasms: Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W55085034

FWCI: 2.97

Cites:

Cited by: 23

Related to: 20